Threshold Announces Initiation Of Dosing With TH-302/Bortezomib In Final Stage Of Ongoing Phase 1/2 Trial Of Patients With Relapsed/Refractory Multiple Myeloma
July 09, 2014 at 07:01 AM EDT
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that dosing has started in the final stage of an ongoing Phase 1/2 trial ...